Genentech is owned by Roche Holding AG, the Swiss pharmaceutical and diagnostics giant headquartered in Basel, Switzerland, which fully acquired Genentech in March 2009 for approximately 46.8 billion dollars.
Genentech is considered the founder of the modern biotechnology industry, having been established in 1976 in South San Francisco, California, by venture capitalist Bob Swanson and biochemist Dr. Herbert Boyer as the world’s first biotechnology company.
Roche Holding AG is listed on the SIX Swiss Exchange and is majority controlled by the Hoffmann-La Roche family, one of Switzerland’s wealthiest and most secretive families, with the remaining shares widely held by public investors.
Knowing who owns Genentech helps explain how the company that pioneered biotechnology has continued to fund breakthrough research for nearly 50 years under the backing of one of Europe’s largest healthcare conglomerates.
This article covers who owns Genentech, what the company does, its history, how it compares to a rival, and key facts about the business.
So let’s get started.
Table of Contents
Who Owns Genentech?
Genentech is owned by Roche Holding AG, which is itself majority controlled by the Hoffmann-La Roche founding family through a complex trust and holding structure.
Roche had held a controlling interest in Genentech since 1990 before acquiring the remaining publicly held shares in the 46.8 billion dollar buyout completed in March 2009.
Genentech operates as a wholly owned independent subsidiary of Roche, maintaining its own Research and Early Development group and its South San Francisco campus as the headquarters for all Roche pharmaceutical operations in the United States.
In 2018, Roche Partnering and Genentech Partnering merged into a single global business development and alliance management team, as confirmed on Genentech’s company profile.
What Does Genentech Do?
Genentech researches and develops medicines primarily for cancer, immunology, neurology, ophthalmology, and rare diseases, operating under the Roche Group’s pharmaceutical division in the United States.
Its portfolio includes some of the world’s most widely used medicines, including Herceptin and Perjeta for breast cancer, Avastin for multiple cancers, Rituxan for blood cancers and autoimmune diseases, and Ocrevus for multiple sclerosis.
XOLAIR (omalizumab) is a Genentech product co-developed with Novartis and the now-acquired Tanox, approved for severe allergic asthma and chronic idiopathic urticaria.
In August 2025, Genentech broke ground on a new manufacturing facility in Holly Springs, North Carolina, its first East Coast manufacturing site, designed to support production of future metabolic medicines including next-generation obesity treatments, as confirmed in Genentech’s official about page.
What Is the History of Genentech?
Genentech was founded on April 7, 1976, by Bob Swanson and Dr. Herbert Boyer, who combined Swanson’s venture capital vision with Boyer’s breakthrough recombinant DNA technology to create the world’s first biotechnology company.
The company achieved its first landmark by producing human insulin using recombinant DNA technology in 1978, and in 1982 Genentech’s insulin became the first recombinant DNA drug ever approved by the FDA.
Roche began investing in Genentech in 1990, acquiring a controlling stake and providing the capital that allowed Genentech to develop its landmark cancer biologics Herceptin, Avastin, and Rituxan through the 1990s and 2000s.
Roche completed its full acquisition for 46.8 billion dollars in March 2009, ending Genentech’s independent stock market listing while preserving its research independence and South San Francisco headquarters.
How Big Is Genentech?
Genentech operates 13 manufacturing and 15 R&D sites across the United States as part of the Roche Group’s American operations, employing approximately 25,000 people across 24 sites in eight US states.
The South San Francisco campus remains one of the largest biotechnology research and commercial operations in the world, spanning over 350 acres on the San Francisco Peninsula.
In May 2025, Genentech agreed to a 2.1 billion dollar partnership with Orionis Biosciences for the development of a small-molecule protein degrader for cancer, reflecting continued large-scale investment in next-generation oncology research.
Roche overall is the fifth-largest pharmaceutical company in the world by revenue and the global leader in cancer treatments, with Genentech forming the core of its US pharmaceutical operations.
Genentech vs Amgen: How Do They Compare?
Genentech and Amgen are both pioneering American biotechnology companies founded in the late 1970s and early 1980s, and are considered co-founders of the modern biotechnology industry.
Genentech is now a wholly owned Roche subsidiary, meaning its research is backed by one of the world’s largest healthcare groups but it no longer operates as an independent public company.
Amgen remains independent and publicly traded on NASDAQ, with 2025 revenues of 36.8 billion dollars and a growing portfolio of biologics, biosimilars, and novel small molecule therapies.
Both companies shaped modern medicine through breakthrough recombinant protein therapies and continue to influence biopharmaceutical research globally from their California headquarters.
Frequently Asked Questions About Genentech
Who owns Genentech?
Genentech is wholly owned by Roche Holding AG of Basel, Switzerland, which completed a 46.8 billion dollar full acquisition in March 2009. Roche itself is majority controlled by the Hoffmann-La Roche founding family.
Is Genentech still independent?
Genentech is not independently publicly traded but operates as a separate business unit within Roche with its own Research and Early Development group. Its South San Francisco campus serves as Roche’s US pharmaceutical headquarters.
Where is Genentech headquartered?
Genentech is headquartered in South San Francisco, California, where it was founded in 1976. It maintains additional manufacturing facilities in Oceanside and Hillsboro, Oregon, and is building a new East Coast facility in Holly Springs, North Carolina.
What is Genentech best known for?
Genentech is best known as the founder of the biotechnology industry and for developing landmark cancer medicines including Herceptin, Avastin, Rituxan, and Perjeta. It also co-developed XOLAIR for severe allergic asthma and chronic hives.
I am Jack Neel, a mechanical engineer, researcher, and writer. I created this website to share my knowledge about different brands and products with you. I research the manufacturers behind the brands and provide you with the information you need to make smart buying decisions.